Evidence map›Paper›PMID 40907578›Full record

ArticleClinical and experimental pediatrics2025

Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children.

Soo-Han Choi, Dong Hyun Kim, Jong Gyun Ahn, Ki Wook Yun, Byung-Wook Eun, Jin Lee, Jina Lee, Taek-Jin Lee, Hyunju Lee, Dae Sun Jo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Soo-Han ChoiDepartment of Pediatrics, Pusan National University School of Medicine, Busan, Korea.
Dong Hyun KimDepartment of Pediatrics, Inha University College of Medicine, Incheon, Korea.
Jong Gyun AhnDepartment of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Ki Wook YunDepartment of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
Byung-Wook EunDepartment of Pediatrics, Eulji University School of Medicine, Daejeon, Korea.
Jin LeeDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea.
Jina LeeDepartment of Pediatrics, University of Ulsan College of Medicine, Ulsan, Korea.
Taek-Jin LeeDepartment of Pediatrics, CHA University School of Medicine, Pocheon, Korea.
Hyunju LeeDepartment of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
Dae Sun JoDepartment of Pediatrics, Jeonbuk National University Medical School, Jeonju, Korea.
Eun Young ChoDepartment of Pediatrics, Chungnam National University College of Medicine, Daejeon, Korea.
Hye-Kyung ChoDepartment of Pediatrics, Ewha Womans University College of Medicine, Seoul, Korea.
Young June ChoeDepartment of Pediatrics, Korea University College of Medicine, Seoul, Korea.
Ui Yoon ChoiDepartment of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea.
Yun-Kyung KimDepartment of Pediatrics, Korea University College of Medicine, Seoul, Korea.
Committee on Infectious Diseases of the Korean Pediatric Society

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal antibody, as a passive immunization to prevent RSV-associated LRTI among infants and young children. Nirsevimab was launched in Korea in February 2025. This report summarizes the recommendations of the Committee on Infectious Diseases of the Korean Pediatric Society regarding the use of nirsevimab. We recommend a single dose of nirsevimab for all neonates born during the RSV season (October to March), as well as all infants younger than 6 months at the start of the RSV season (i.e., those born between April and September of that year). Nirsevimab should be administered shortly after birth (within the first week of life) to neonates born during the RSV season and just before or early in the season (late September to October) to infants entering their first RSV season. Nirsevimab may also be considered for children younger than 2 years of age who are at increased risk of severe RSV disease and entering their second RSV season.

Indexed as

ImmunizationLong-acting monoclonal antibodiesMonoclonal antibodiesRespiratory syncytial viruses

Identifiers

PMID40907578
PMCPMC12488281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.